Loading clinical trials...
Loading clinical trials...
A Six Month, Open-label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera(Registered)) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-diabetic Agents
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
Age
35 - 80 years
Sex
ALL
Healthy Volunteers
No
Gain Medical Center
Coquitlam, British Columbia, Canada
Misericordia Health Centre
Winnipeg, Manitoba, Canada
Maritime Research Center
Bathurst, New Brunswick, Canada
Office of Dr. Salim Sunderji
London, Ontario, Canada
Orillia Soldier's Memorial Hospital
Orillia, Ontario, Canada
Douglas Tweel M.D. Professional Corporation
Charlottetown, Prince Edward Island, Canada
Laboratoire Sante Le Gaspesien Inc.
Bonaventure, Quebec, Canada
Centre de santé et de services sociaux de Chicoutimi, Centre de médecine genique communataire
Chicoutimi, Quebec, Canada
Rhodin Recherche Clinique
Drummondville, Quebec, Canada
Q & T Research Outaouais Inc.
Gatineau, Quebec, Canada
Start Date
March 6, 2006
Primary Completion Date
February 19, 2008
Completion Date
February 19, 2008
Last Updated
April 2, 2019
354
ACTUAL participants
Inhaled Insulin (Exubera)
DRUG
Standard of Care
OTHER
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03821636